We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $4.94B
1-Year Est. Return 244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
Cap. Flow
+$314M
Cap. Flow %
6.35%
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$82.7M
2
ABVX
Abivax
ABVX
+$65.2M
3
COAG
Hemab Therapeutics
COAG
+$57.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$53M
5
KLRA
Kailera Therapeutics
KLRA
+$48.7M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$60.4M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$42.9M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$41.8M
4
RVMD icon
Revolution Medicines
RVMD
+$30.8M
5
KYMR icon
Kymera Therapeutics
KYMR
+$21.6M

Sector Composition

Rank Sector Weight
1 Healthcare 92.94%
2 Technology 3.57%
3 Communication Services 1.85%
4 Financials 0.87%
5 Consumer Discretionary 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$5.87B
$527M 10.66%
9,575,013
-1,250,000
-12% -$60.4M
KYMR icon
2
Kymera Therapeutics
KYMR
$9.78B
$337M 6.81%
2,935,830
-251,000
-8% -$21.6M
ERAS icon
3
Erasca
ERAS
$5.26B
$209M 4.23%
11,397,781
+153,535
+1% +$2.2M
MANE
4
Veradermics Inc
MANE
$4.71B
$204M 4.12%
1,655,374
+150,000
+10% +$14.1M
TNGX icon
5
Tango Therapeutics
TNGX
$3.77B
$193M 3.91%
6,179,364
+522,259
+9% +$12.9M
RVMD icon
6
Revolution Medicines
RVMD
$41.3B
$169M 3.41%
900,000
-210,980
-19% -$30.8M
BCAX
7
Bicara Therapeutics
BCAX
$1.46B
$166M 3.37%
5,602,970
-200,000
-3% -$4.46M
ARWR icon
8
Arrowhead Research
ARWR
$9.72B
$140M 2.83%
1,715,476
+100,000
+6% +$7.39M
ONC
9
BeOne Medicines Ltd
ONC
$41.4B
$133M 2.68%
465,000
– –
EWTX icon
10
Edgewise Therapeutics
EWTX
$4.85B
$129M 2.62%
3,184,629
-1,245,634
-28% -$42.9M
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$6.8B
$126M 2.55%
1,136,275
+410,764
+57% +$37.1M
LXRX icon
12
Lexicon Pharmaceuticals
LXRX
$908M
$106M 2.15%
44,303,518
– –
ELVN icon
13
Enliven Therapeutics
ELVN
$3.58B
$90.1M 1.82%
1,774,411
+1,028,185
+138% +$43.7M
SYRE icon
14
Spyre Therapeutics
SYRE
$8.11B
$86M 1.74%
968,598
+150,000
+18% +$10.9M
PBLS
15
Parabilis Medicines Inc
PBLS
$4.56B
$81.9M 1.66%
+2,992,259
New +$82.7M
XENE icon
16
Xenon Pharmaceuticals
XENE
$3.78B
$79.6M 1.61%
1,318,564
– –
SLDB icon
17
Solid Biosciences
SLDB
$916M
$76.8M 1.55%
7,690,405
– –
ABVX
18
Abivax
ABVX
$9.03B
$76.8M 1.55%
+576,000
New +$65.2M
COAG
19
Hemab Therapeutics
COAG
$1.77B
$76.6M 1.55%
+2,086,834
New +$57.6M
RCUS icon
20
Arcus Biosciences
RCUS
$3.3B
$74.6M 1.51%
2,420,430
-586,647
-20% -$14.5M
COGT icon
21
Cogent Biosciences
COGT
$5.55B
$72M 1.46%
1,859,279
+150,000
+9% +$5.25M
RLAY icon
22
Relay Therapeutics
RLAY
$3.99B
$68.3M 1.38%
+3,650,000
New +$53M
TSHA icon
23
Taysha Gene Therapies
TSHA
$1.64B
$67.1M 1.36%
9,846,579
+1,016,666
+12% +$6.02M
DFTX
24
Definium Therapeutics
DFTX
$5.28B
$66.8M 1.35%
1,419,493
+500,000
+54% +$12.4M
STOK icon
25
Stoke Therapeutics
STOK
$1.81B
$65.3M 1.32%
1,995,347
– –
1
2 3 4 5

Similar funds

AAS
Ameritas Advisory Services Lincoln, Nebraska $4.96B AUM 27.52% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
FC
Freemont Capital Singapore $4.9B AUM 11.61% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $4.99B AUM 23.08% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Siren LLC's Q2 2026 Portfolio in Review

As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.

  • Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
  • Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
  • Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
  • Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
  • Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
  • Siren LLC opened 26 new positions and closed 9 in Q2 2026.
  • Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.